Israel's Protalix BioTherapeutics (PLX [1]) has seen its shares skyrocket 415 percent this year. And its success developing a new Gaucher disease therapy appears to have attracted some intense interest from Pfizer.
Reporters at TheMarker say that a delegation from Pfizer visited Protalix's facilities in Israel in anticipation of a development deal and possible buyout. Protalix Chief Executive David Aviezer has already said he expects to have a pact in place by the end of this year. The company has made waves in the Gaucher disease market with a successful late-stage trial of Uplyso. A likely contender to Cerezyme, the drug is being readied for an NDA after Genzyme announced problems with contamination at the facility that makes its extraordinarily expensive drug.
- read the report [2] from Reuters
Related Articles:
Protalix boosted by late-stage Gaucher success [3]
Protalix gets fast track for its red-hot Gaucher drug [4]
Protalix shares rocket after FDA approves temp drug use [5]
FDA turns to Protalix for new Gaucher drug [6]
Links:
[1] http://www.google.com/finance?client=ob&q=AMEX:PLX
[2] http://www.reuters.com/article/americasMergersNews/idUSL229448820091102
[3] http://www.fiercebiotech.com/story/protalix-boosted-late-stage-gaucher-success/2009-10-15
[4] http://www.fiercebiotech.com/story/protalix-gets-fast-track-its-red-hot-gaucher-drug/2009-08-25
[5] http://www.fiercebiotech.com/story/protalix-shares-rocket-after-fda-approves-temp-drug-use/2009-08-17
[6] http://www.fiercebiotech.com/story/fda-turns-protalix-new-gaucher-drug/2009-07-06